Literature DB >> 18306262

Modular phosphite-oxazoline/oxazine ligand library for asymmetric pd-catalyzed allylic substitution reactions: scope and limitations-origin of enantioselectivity.

Montserrat Diéguez1, Oscar Pàmies.   

Abstract

A library of phosphite-oxazoline/oxazine ligands L1-L15 a-h has been synthesized and screened in the Pd-catalyzed allylic substitution reactions of several substrate types. These series of ligands can be prepared efficiently from easily accessible hydroxyl amino acid derivatives. Their modular nature enables the substituents/configurations in the oxazoline/oxazine moiety, alkyl backbone chain and in the biaryl phosphite moiety to be easily and systematically varied. By carefully selecting the ligand components, therefore, high regio- and enantioselectivities (ee values up to 99 %) and good activities have been achieved in a broad range of mono- and disubstituted linear hindered and unhindered liner and cyclic substrates. The NMR studies on the Pd-pi-allyl intermediates provide a deeper understanding about the effect of the ligand parameters on the origin of enantioselectivity. It also indicates that the nucleophilic attack takes place predominantly at the allylic terminal carbon atom located trans to the phosphite moiety.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18306262     DOI: 10.1002/chem.200701636

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  2 in total

1.  Allylic alkylations catalyzed by palladium-bis(oxazoline) complexes derived from heteroarylidene malonate derivatives.

Authors:  Lei Liu; Hongli Ma; Bin Fu
Journal:  Molecules       Date:  2012-02-17       Impact factor: 4.411

2.  Proofreading experimentally assigned stereochemistry through Q2MM predictions in Pd-catalyzed allylic aminations.

Authors:  Jessica Wahlers; Jèssica Margalef; Eric Hansen; Armita Bayesteh; Paul Helquist; Montserrat Diéguez; Oscar Pàmies; Olaf Wiest; Per-Ola Norrby
Journal:  Nat Commun       Date:  2021-11-18       Impact factor: 14.919

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.